Navigation Links
New Drug Promising for Advanced Thyroid Cancer
Date:9/19/2010

By Steven Reinberg
HealthDay Reporter

FRIDAY, Sept. 17 (HealthDay News) -- A targeted drug called pazopanib could prove effective against difficult-to-treat cases of thyroid cancer cases, researchers say.

Most thyroid cancers can be treated with surgery or radioiodine, but about 5 percent of patients will develop an aggressive, life-threatening form of the disease.

Pazopanib (Votrient), already approved by the U.S. Food and Drug Administration for treating advanced kidney cancer, works by inhibiting growth of blood vessels essential for tumor growth and survival.

"Thyroid cancers, when they grow, they need to form a lot of blood vessels," explained researcher Dr. Julian Molina, an assistant professor of oncology at the Mayo Clinic and co-author of the study. "For blood vessels to grow, the growth factor VEGF is required, and the drug targets this protein," he said.

Not only does the drug block production of new blood vessels, it also interferes with the tumor cells' ability to continue growing, Molina said.

Pazopanib, a pill that's taken daily, doesn't have the severe side effects of standard chemotherapy, Molina said. But it is expensive. According to the U.S. Department of Health and Human Services, the average wholesale price, which is used to set drug reimbursements, is $6,595 a month.

For this phase 2 study, published in the Sept. 17 online edition of The Lancet Oncology, Molina and colleagues tested the efficacy and safety of pazopanib in 37 patients with advanced, rapidly progressing thyroid cancer.

About half of the patients --18 -- had a partial response to the drug, meaning their tumor shrank 30 percent or more, Molina said. None had a complete response, in which the tumor disappears completely, he added.

Twelve patients are still responding to the drug about a year later. "Patients take the drug until the drug is no longer effective," Molina said, noting these patients still take pazopanib every day.

Side effects were commonplace but typically mild. The most usual were diarrhea, hypertension, and an increase in a liver enzyme called aminotransferase. However, 15 patients had to have their dose lowered because of side effects, the researchers note.

The U.S. National Cancer Institute funded the study.

Molina noted that larger phase 3 trials will start soon, and he hopes the drug, made by GlaxoSmithKline, will be approved for treating advanced thyroid cancer.

"One of the goals in cancer care is to make cancer a chronic disease," Molina said. "If we can make cancer something like that, where your pills keep your disease controlled, that's a good goal," he said.

One expert said that any effective therapy would be welcome.

"There are not a lot of treatment options available for people with advanced thyroid cancer," said Dr. Leonard Lichtenfeld, deputy chief medical officer at the American Cancer Society.

While the study results will need to be replicated and tested against other treatment options before pazopanib can be approved as a therapy for thyroid cancer, he agreed that the drug shows promise.

"Targeted therapies are providing some effective treatment options for patients with diseases that traditionally have been difficult to treat," he said. "I find that very helpful and very exciting."

More information

For more information on thyroid cancer, visit the American Cancer Society.

SOURCES: Julian Molina, M.D., Ph.D., assistant professor of oncology, Mayo Clinic, Rochester, Minn.; Leonard Lichtenfeld, M.D., M.A.C.P., deputy chief medical officer, American Cancer Society, Atlanta; Sept. 17, 2010, The Lancet Oncology, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Kings College London reveals promising techniques for extending the life of an organ transplant
2. Promising treatment for metastatic melanoma fast tracked by FDA
3. A promising target for developing treatments against Parkinsons disease
4. Natural lung material is promising scaffold for engineering lung tissue using embryonic stem cells
5. Depression overlooked in patients with hepatitis C; compromising HCV therapy
6. BRAF inhibitor shows promising preclinical activity against melanoma
7. New promising therapy against systemic sclerosis
8. Is the current recession compromising hospital quality?
9. Peaches, plums induce deliciously promising death of breast cancer cells
10. U of A discovery offers promising research for spinal-cord injury treatments
11. Study identifies promising treatment for aggressive lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug Promising for Advanced Thyroid Cancer
(Date:5/5/2016)... ... May 05, 2016 , ... A local study examining ... than 40 percent of participating fifth-grade students already have or are at risk ... Clinical Research in the Division of Pulmonary, Allergy and Critical Care Medicine at ...
(Date:5/5/2016)... NEW YORK (PRWEB) , ... May 05, 2016 , ... ... and swimming safety – today announced a new partnership to reach nearly 1 million ... can happen in an instant and is the leading cause of accidental death in ...
(Date:5/5/2016)... ... May 05, 2016 , ... Sun ... talk highlighting the organization’s successful Care Transitions program at the 9th ... was titled “Minimizing Costs in the Post-Acute Environment Through Effective Transitions of Care.” ...
(Date:5/5/2016)... ... , ... The 2016 Nike Soccer Camp will be directed by the 2015 ... Together they bring their winning Vandals coaching philosophy to young athletes. Programs are offered ... high school players. Session dates are as follows: , Youth Day Camp – July ...
(Date:5/5/2016)... ... May 05, 2016 , ... Talent Tech Labs (TTL) is pleased ... of National Nurses Week (May 6-12). Currently, HireNurses is a job listing ... into the Talent Tech Lab Virtual Incubation program, they will dramatically expand the functionality ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... WASHINGTON D.C. , May 4, 2016 /PRNewswire/ ... its member companies concluded a series of free ... training in global requirements for Good ... part of quality assurance which ensures that products are ... by the marketing authorization (MA) or product specification. Only ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Ischemic Stroke Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Ischemic Stroke Market and Competitive Landscape Highlights ... Stroke pipeline products, Acute Ischemic Stroke epidemiology, ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute lymphocytic Leukemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Leukemia Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Lymphocytic Leukemia epidemiology, Acute ...
Breaking Medicine Technology: